Cargando…

Efficacy and safety of omalizumab against chronic spontaneous urticaria: Real-world study from China()

BACKGROUND: Omalizumab is an effective treatment for chronic spontaneous urticaria (CSU) patients aged ≥12 years, but its efficacy in patients aged <12 years has not been fully documented. We evaluated the therapeutic efficacy and safety of omalizumab in Chinese CSU population across all age grou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Ao, Yun, Yuhui, Wen, Zhihua, Gao, Yingxia, Qi, Shuzhen, Zhang, Yu, Liang, Yunsheng, Yao, Xu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	World Allergy Organization 2022
Materias:	Full-Length Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672950/ https://www.ncbi.nlm.nih.gov/pubmed/36438194 http://dx.doi.org/10.1016/j.waojou.2022.100719

Ejemplares similares

The impact of home treatment and self-administration of omalizumab on chronic urticaria
por: Wiuff, Anne Christine, et al.
Publicado: (2022)

Omalizumab's efficacy and safety against chronic spontaneous urticaria
por: Özdemir, Öner
Publicado: (2023)

Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence
por: Metz, Martin, et al.
Publicado: (2020)

Omalizumab on Chronic Spontaneous Urticaria and Chronic Inducible Urticaria: A Real-World Study of Efficacy and Predictors of Treatment Outcome
por: Jeong, Soo Hyun, et al.
Publicado: (2022)

Efficacy and safety of omalizumab therapy in urticaria vasculitis
por: Petrelli, Fiorella, et al.
Publicado: (2022)

Sex differences in the efficacy of omalizumab in the treatment of chronic spontaneous urticaria
por: Sirufo, Maria Maddalena, et al.
Publicado: (2022)

Efficacy and safety of omalizumab in Chinese patients with anti‐histamine refractory chronic spontaneous urticaria
por: Yuan, Weiru, et al.
Publicado: (2022)

OMALIZUMAB IN TREATMENT-RESISTANT CHRONIC SPONTANEOUS URTICARIA
por: Godse, Kiran V
Publicado: (2011)

Profile of omalizumab in the treatment of chronic spontaneous urticaria
por: Labrador-Horrillo, Moises, et al.
Publicado: (2015)

Omalizumab is effective in nasal polyposis with or without asthma, a real-life study
por: Tat, Tuğba Songül
Publicado: (2022)

Multicentric and Observational Study of Omalizumab for Chronic Spontaneous Urticaria in Real-Life in Colombia
por: García-Gómez, Elizabeth, et al.
Publicado: (2022)

A Real-World Analysis of Relapse Rate and Efficacy of a Restricted Monthly Dose of Omalizumab in Recalcitrant Chronic Spontaneous Urticaria in India
por: Sardana, Kabir, et al.
Publicado: (2020)

Case Report: Omalizumab for Chronic Spontaneous Urticaria in Pregnancy
por: Liao, Shuang-Lu, et al.
Publicado: (2021)

Ligelizumab improves angioedema, disease severity and quality-of-life in patients with chronic spontaneous urticaria()
por: Metz, Martin, et al.
Publicado: (2022)

Expert consensus on the use of omalizumab in chronic urticaria in China()
por: Zhao, Zuotao, et al.
Publicado: (2021)

A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real‐world study in Belgium
por: Lapeere, H., et al.
Publicado: (2019)

Omalizumab Treatment in Patients With Cholinergic Urticaria: A Real-World Retrospective Study in Korea
por: Kim, Ji Hye, et al.
Publicado: (2020)

Real-World Characteristics and Treatment Patterns in Patients with Urticaria Initiating Omalizumab in the United States
por: Ke, Xuehua, et al.
Publicado: (2018)

Omalizumab in chronic spontaneous urticaria (CSU): experience in three cases
por: Valle, Solange Oliveira Rodrigues, et al.
Publicado: (2015)

Omalizumab is effective in the treatment of difficult-to-treat chronic spontaneous urticaria
por: Forgie, Jennifer, et al.
Publicado: (2014)

Use of biologics in chronic spontaneous urticaria – beyond omalizumab therapy?
por: Metz, Martin, et al.
Publicado: (2021)

Omalizumab treatment for chronic spontaneous urticaria: data from Turkey
por: Kara, Rabia Oztas, et al.
Publicado: (2022)

Cost‐effectiveness of personalized omalizumab dosing for chronic spontaneous urticaria
por: Denman, Sarah, et al.
Publicado: (2022)

Omalizumab for chronic spontaneous urticaria in “complex” patients: data from real-life clinical practice
por: Vollono, Laura, et al.
Publicado: (2019)

Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both
por: Chen, Yudi, et al.
Publicado: (2021)

Long-Term Safety of Omalizumab in Children with Asthma and/or Chronic Spontaneous Urticaria: A 4-Year Prospective Study in Real Life
por: Galletta, Francesca, et al.
Publicado: (2023)

Omalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells
por: Serrano-Candelas, Eva, et al.
Publicado: (2017)

Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients
por: Dekkers, Coco, et al.
Publicado: (2021)

Case Report: Safety and Efficacy of Omalizumab in a 13-Year-Old Patient With Chronic Spontaneous Urticaria and Type 1 Diabetes
por: Del Barba, Paolo, et al.
Publicado: (2022)

Position statement for the use of omalizumab in the management of chronic spontaneous urticaria in Indian patients
por: Godse, Kiran, et al.
Publicado: (2016)

Refractory Chronic Spontaneous Urticaria Treated With Omalizumab in an Adolescent With Common Variable Immunodeficiency
por: Comberiati, Pasquale, et al.
Publicado: (2019)

Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria
por: Graham, Jonathan, et al.
Publicado: (2016)

Improving of psychological status and inflammatory biomarkers during omalizumab for chronic spontaneous urticaria
por: Diluvio, Laura, et al.
Publicado: (2020)

Response of FcεRI‐bearing leucocytes to omalizumab in chronic spontaneous urticaria
por: Alizadeh Aghdam, Mehran, et al.
Publicado: (2020)

Exploring Machine Learning Techniques to Predict the Response to Omalizumab in Chronic Spontaneous Urticaria
por: Sardina, Davide Stefano, et al.
Publicado: (2021)

Omalizumab Reduces Unplanned Healthcare Interactions in Irish Patients With Chronic Spontaneous Urticaria
por: Ridge, Katie, et al.
Publicado: (2021)

The course of COVID-19 in patients with chronic spontaneous urticaria receiving omalizumab treatment
por: Atayik, E., et al.
Publicado: (2022)

Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status
por: Casale, Thomas B., et al.
Publicado: (2023)

Case report: Severe chronic spontaneous urticaria successfully treated with omalizumab and dupilumab
por: Puxkandl, Viktoria, et al.
Publicado: (2023)

Omalizumab for chronic urticaria in Latin America
por: Wilches, Paul, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_s8n3b1lj4r35majus2tts5hroe